Acrivon Therapeutics (NASDAQ:ACRV) Earns Outperform Rating from BMO Capital Markets

BMO Capital Markets restated their outperform rating on shares of Acrivon Therapeutics (NASDAQ:ACRVFree Report) in a report published on Monday morning, Benzinga reports. The firm currently has a $18.00 price objective on the stock.

Several other equities research analysts also recently weighed in on the stock. HC Wainwright reaffirmed a buy rating and issued a $20.00 price objective on shares of Acrivon Therapeutics in a report on Thursday, March 28th. JMP Securities reissued a market outperform rating and issued a $14.00 price target on shares of Acrivon Therapeutics in a report on Monday. Seven investment analysts have rated the stock with a buy rating, According to data from MarketBeat, Acrivon Therapeutics has an average rating of Buy and an average target price of $21.29.

View Our Latest Report on Acrivon Therapeutics

Acrivon Therapeutics Stock Down 0.4 %

ACRV stock opened at $6.66 on Monday. The company has a market capitalization of $150.78 million, a P/E ratio of -2.44 and a beta of 1.94. The company has a 50-day simple moving average of $4.85 and a 200 day simple moving average of $5.33. Acrivon Therapeutics has a fifty-two week low of $3.19 and a fifty-two week high of $14.30.

Institutional Investors Weigh In On Acrivon Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of ACRV. Marshall Wace LLP acquired a new stake in Acrivon Therapeutics during the 4th quarter worth about $14,092,000. BlackRock Inc. acquired a new stake in Acrivon Therapeutics during the 1st quarter worth about $6,018,000. Geode Capital Management LLC acquired a new stake in Acrivon Therapeutics during the 1st quarter worth about $2,226,000. State Street Corp acquired a new stake in Acrivon Therapeutics during the 1st quarter worth about $1,083,000. Finally, Vanguard Group Inc. raised its holdings in Acrivon Therapeutics by 16.2% during the 3rd quarter. Vanguard Group Inc. now owns 468,407 shares of the company’s stock worth $4,478,000 after buying an additional 65,132 shares during the period. 71.62% of the stock is owned by institutional investors and hedge funds.

About Acrivon Therapeutics

(Get Free Report)

Acrivon Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates.

Further Reading

Analyst Recommendations for Acrivon Therapeutics (NASDAQ:ACRV)

Receive News & Ratings for Acrivon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acrivon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.